2004
DOI: 10.1111/j.1526-4610.2004.04127.x
|View full text |Cite
|
Sign up to set email alerts
|

Disability in Chronic Migraine Patients With Medication Overuse: Treatment Effects at 1‐Year Follow‐up

Abstract: Chronic migraine accompanied with medication overuse led to the considerable disability prior to treatment. However, notable improvement occurred coincident with the treatment. This suggests that successful treatment has more wide-ranging positive benefits beyond mere symptom reduction. To our knowledge, this is the first investigation where the MIDAS questionnaire has been used prospectively as an outcome measure in patients with chronic migraine and medication overuse to assess disability subsequent to a sem… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
48
0
2

Year Published

2004
2004
2018
2018

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 43 publications
(52 citation statements)
references
References 27 publications
2
48
0
2
Order By: Relevance
“…The patients arrived to the hospital at 9.00 am; they completed the infusional therapy and left the hospital at 4 pm. The treatment consisted of the following [5]: (1) intravenous hydration for a period of 5-6 days; (2) intravenous steroids for the first 5 days followed by oral prescription for other 5 days; (3) diazepam per os in 2 prescription per day; (4) ev or im metoclopramide or indomethacine when needed for intense rebound headache [5].…”
Section: Methodsmentioning
confidence: 99%
“…The patients arrived to the hospital at 9.00 am; they completed the infusional therapy and left the hospital at 4 pm. The treatment consisted of the following [5]: (1) intravenous hydration for a period of 5-6 days; (2) intravenous steroids for the first 5 days followed by oral prescription for other 5 days; (3) diazepam per os in 2 prescription per day; (4) ev or im metoclopramide or indomethacine when needed for intense rebound headache [5].…”
Section: Methodsmentioning
confidence: 99%
“…Regarding relapse, recent studies indicate that the highest risk is in the first 12 months, although different percentages are reported by various authors (22-44 % in Trucco et al [41]; 60-75 % in Zidverc et al [42] and Baumgartner et al [43]; or 40-60 % in Andrasik [15], Katsarava [44], Hagen et al [45], and Fritsche et al [46]). The risk decreases, however, if medication overuse is avoided for 12 months after withdrawal, and in general, MOH treatment is considered successful if the improvement obtained after withdrawal/detoxification with or without prophylaxis is maintained at 1-year follow-up [42,[47][48][49][50][51]. Several factors are considered a risk for relapse: male sex, a diagnosis of tension-type headache or mixed headache, frequency of the primary headache, higher severity of the migraine condition, long duration of drug overuse, greater number of previous prophylactic treatments, intake of combination analgesic products (e.g., one or more NSAIDs with caffeine or codeine) or of codeine-containing drugs, ergotamine or triptan withdrawal more than analgesic withdrawal, use of the same drug that has caused overuse, lower improvement after drug withdrawal, reduced sleep quality, and high levels of body pain and of disability score for chronic headache [12].…”
Section: Ichd-3 Beta 2013mentioning
confidence: 99%
“…В большинстве случа-ев рекомендуется полная и одномоментная отмена пре-парата. Постепенная отмена рекомендуется только при злоупотреблении барбитуратами или неудачных пред-шествующих попытках отмены [24]. Основные принципы European Academy Neurology (EAN) по отмене абузусного препарата представлены в таблице 2 [25].…”
Section: поведенческие факторыunclassified